Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|March 30, 2021
Dr. Primo Lara on the need for multidisciplinary care in kidney cancer
Author(s)Urology Times staff
Advertisement
Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5